Papermache itself is one big study: whenever we find new innovation in management or marketing techniques, we will publish our findings in our database. Furthermore, while we are private held company, we will publish our financials in the same way as public companies. This will allow a whole new level of transparency and accountability.
Here's the current hypothesis: graduate schools, specifically medical schools, review portfolios of undergraduate work published on Papermache in supplement to applications and select candidates based on research completed at the undergraduate level. This will contribute to better research and researchers at the graduate school level.
The pharmaceutical industry has a historically problematic relationship with medical schools in that their influence leads to biased research and expensive, mediocre drugs. (source: https://goo.gl/j3UTo) It's the notion that "competitive research" in that innovations developed by pharmaceutical companies are aggressively protected and used against their competitiors. Hundreds of millions of dollars are then spent on R&D, justfiying high costs for medicine. This violates the true fundamentals of research which is inherently collaborative.
If the publishing model is changed so that research stays collaborative and at the medical school level and leased to pharmaceutical companies, pharmaceutical companies can spend less on R&D and focus instead on manufacturing. This will lead to cheaper, more effective drugs and less biased research.
Papermache hopes to become the infrastructure that changes the publishing model so that the research stays at the unversity level and decreases pharmaceutical influence over medical schools.
We will concert our efforts to have medical schools review portfolios, thereby incentivizing pre-med university student participation.
